VES001

DRUG2 trials

Sponsors

Vesper Biotechnologies ApS, Mads Kjolby

Conditions

Asymptomatic ConditionDementiaDementia, FrontotemporalFrontotemporal Dementia

Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 in Healthy Participants

CompletedNCT06226064

Vesper Biotechnologies ApSDementia, Frontotemporal

Start: 2023-10-11End: 2024-07-26Updated: 2024-08-22

Study in Asymptomatic GRN-FTD Patients to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001

CompletedNCT06705192

Mads KjolbyAsymptomatic Condition, Dementia, Frontotemporal Dementia

Start: 2024-12-12End: 2025-08-05Updated: 2025-08-24